Skip to content

Clinical trials

Completed Metabolic Diseases trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Metabolic Diseases Phase: Not applicable Status: Completed Clear all

176 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20031
20041
20051
20071
20093
20104
201110
201211
20136
201411
201513
201618
20178
201817
20198
202012
202116
202212
202313
20245
20254

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed176

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Singapore Institute of Food and Biotechnology Innovation7
University of Aarhus6
Maastricht University Medical Center4
Universidad Santo Tomas4
Steno Diabetes Center Copenhagen3
University of Copenhagen3
University of Michigan3
AdventHealth Translational Research Institute2
Assistance Publique - Hôpitaux de Paris2
Clinical Nutrition Research Center, Illinois Institute of Technology2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Metabolic Diseases176
Obesity44
Diabetes Mellitus37
Glucose Metabolism Disorders31
Diabetes Mellitus, Type 227
Endocrine System Diseases24
Insulin Resistance22
Overweight14
Cardiovascular Diseases12
Metabolic Syndrome12

Trials

Showing 1 to 25 of 176. Each trial links to its page on Pharma Observatory.

76 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.